3 Humongous Health-Care Stocks This Week

This year will go down in the record books as one of the best ever for health-care stocks. And the year isn't ending on a disappointing note. Several health-care stocks experienced huge gains during the short holiday week. Here are the three biggest winners.

High C
Provectus Biopharmaceuticals
  (NYSEMKT: PVCT  ) stands out as the top health-care stock on our list. Shares skyrocketed 45% on momentum from an important "type C" meeting held with the U.S. Food and Drug Administration last week.

On Dec. 18, Provectus announced that it had met two days earlier with the FDA about a pathway to approval for the company's melanoma drug PV-10. There really wasn't much that the company could share about the meeting, but the news was enough to excite investors. 

Provectus is gearing up for a phase 3 pivotal trial of PV-10 in treating melanoma, which received orphan drug designation from the FDA in 2011. An early stage trial of the drug in treating breast cancer has also been completed with another under way targeting liver cancer. 

Great expectations
There wasn't much in the form of news this week for Inovio Pharmaceuticals (NASDAQ: INO  ) , but that didn't matter. Shares soared nearly 32% anyway.

Great expectations explain much of Inovio's rapid ascent of late. Institutional investors have scooped up big stakes in the clinical-stage vaccine developer this year. Inovio's synthetic DNA vaccines, particularly one targeting cervical dysplasia, continue to generate huge interest. 

All of these expectations helped propel Inovio to near the top of the rankings for stock performance in 2013. With the past week's gains, Inovio's shares are up a whopping 494% year to date.

Good news frontward and backward
United Therapeutics
(NASDAQ: UTHR  ) lands the third spot on our humongous list, with shares jumping 29% for the week. FDA approval of pulmonary arterial hypertension, or PAH, drug Orenitram served as the catalyst.

This latest approval garnered United Therapeutics its fifth for a PAH treatment. The company counts three products already on the market: Remodulin, Tyvaso, and Adcirca. 

Orenitram claims a unique difference from United Therapeutics' prior drugs, though. It's named after the company's founder, Martine Rothblatt. In case you don't spot the connection, Orenitram is "Martine Ro" spelled backwards. 

FDA approval of Orenitram also meant good news for Supernus Pharmaceuticals (NASDAQ: SUPN  ) . Supernus developed technology used in the drug. The company stands to gain milestone and royalty payments from United Therapeutics.

Watching out
Which of this week's three top stocks should investors watch closely? The easy answer is all of them.

Investors will find out more from Provectus in mid-January, after the FDA releases meeting minutes from the PV-10 discussion. Inovio has several presentations in the first quarter that could serve as additional catalysts for the stock. And United Therapeutics will now have yet another PAH drug to generate revenue. Investors might want to keep their eyes on all of these stocks into 2014.

Another hot stock to watch next year
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 28, 2013, at 6:16 PM, mplaut100 wrote:

    Most observers and followers expect that Provectus will get approval from the FDA to skip a full Phase 3 study. The hope is for BTD (BreakThrough Designation) or AA (Accelerated Approval). The FDA is expected to provide the company with the official minutes of the meeting on or before January 16. The company has disclosed that it has had worldwide discussions with various companies for various business arrangements. It also has another drug, PH-10, for skin ailments.

    These developments can drive the price much, much higher.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2777976, ~/Articles/ArticleHandler.aspx, 10/30/2014 3:05:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement